Pediatric Endocrinology Diabetes and Metabolism
en ENGLISH
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

without publication fees

Zintegrowane z publons

integrated with publons
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Opis przypadku

Przedwczesne dojrzewanie i prawidłowe wzrastanie po leczeniu czaszkogardlaka: opis przypadku i przegląd piśmiennictwa

Martyna Soloch
1
,
Katarzyna Robakowska
2
,
Natalia Popłonyk
1
,
Monika Hylińska
1
,
Katarzyna Janeczek
1
,
Kamil Dyrka
2, 3
,
Katarzyna Jończyk-Potoczna
4
,
Katarzyna Derwich
5
,
Marek Niedziela
2
,
Monika Obara-Moszyńska
2

  1. Student Scientific Society, Poznan University of Medical Sciences, Poland
  2. Department of Pediatric Endocrinology and Rheumatology, Institute of Pediatrics, Poznan University of Medical Sciences, Poland
  3. Doctoral School, Poznan University of Medical Sciences, Poland
  4. Department of Pediatric Radiology, Institute of Pediatrics, Poznan University of Medical Sciences, Poland
  5. Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, Poland
Pediatr Endocrinol Diabetes Metab 2026; 32
DOI: https://doi.org/10.5114/pedm.2026.159282
Data publikacji online: 2026/02/23
Plik artykułu:
- 0403_Precocious puberty.pdf  [3.99 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Cantas-Orsdemir S, Eugster EA. Update on central precocious puberty: from etiologies to outcomes. Expert Rev Endocrinol Metab 2019; 14: 123–130. doi: 10.1080/17446651.2019.1575726. 
2. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013; 98: 2198–2207. doi: 10.1210/jc.2013-1024.
3. Bräuner EV, Busch AS, Eckert-Lind C, et al. Trends in the Incidence of Central Precocious Puberty and Normal Variant Puberty Among Children in Denmark, 1998 to 2017. JAMA Netw Open 2020; 3: e2015665. doi: 10.1001/jamanetworkopen.2020.15665.
4. Brito VN, Canton APM, Seraphim CE, et al. The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty [published correction appears in Endocr Rev 2023; 44: 355]. Endocr Rev 2023; 44: 193–221. doi: 10.1210/endrev/bnac020.
5. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016; 4: 265–274. doi: 10.1016/S2213-8587(15)00380-0.
6. Jakubek-Kipa K, Drachal E, Mazur A. Przedwczesne dojrzewanie płciowe. Pediatr Dypl 2014; 18: 27–35.
7. Gracjasz-Palikij I, Paprocka J, Gawlik A. Central precocious puberty – etiology with particular consideration of neurological causes. Arch Med Sci 2024; 20: 831–838. doi: 10.5114/aoms.2020.96394.
8. Jarzabek-Bielecka G, Warchoł-Biedermann K, Sowińska E, Wachowiak-Ochmańska K. Przedwczesne dojrzewanie płciowe [Precocious puberty]. Ginekol Pol 2011; 82: 281–286.
9. Mogensen SS, Aksglaede L, Mouritsen A, et al. Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty. PLoS One 2012; 7: e29829. doi: 10.1371/journal.pone.0029829.
10. Chemaitilly W, Merchant TE, Li Z, et al. Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes. Clin Endocrinol (Oxf) 2016; 84: 361–371. doi: 10.1111/cen.12964.
11. van Iersel L, Li Z, Srivastava DK, et al. Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. J Clin Endocrinol Metab 2019; 104: 6101–6115. doi: 10.1210/jc.2019-00834.
12. Darzy KH, Shalet SM. Hypopituitarism after cranial irradiation. J Endocrinol Invest 2005; 28: 78–87.
13. Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004; 14: 118–124. doi: 10.1016/j.ghir.2004.03.038.
14. Darzy KH, Shalet SM. Hypopituitarism following Radiotherapy Revisited. Endocr Dev 2009; 15: 1–24. doi: 10.1159/000207607. 
15. Perek D, Perek-Polnik M. Nowotwory ośrodkowego układu nerwowego: rozpoznawanie i leczenie. Pediatr Dypl 2013; 17: 23–32.
16. Hussein Z, Glynn N, Martin N, et al. Temporal trends in craniopharyngioma management and long-term endocrine outcomes: A multicentre cross-sectional study. Clin Endocrinol 2021; 94: 242–249. doi: 10.1111/cen.14334.
17. Gan Wei-Hoong, Morillon P, Albanese A, et al. National UK guidelines for the management of paediatric craniopharyngioma. Lancet Diabetes Endocrinol 2023; 11: 694–706. doi: 10.1016/S2213-8587(23)00162-6. 
18. Chen YD, Shu SG, Chi CS, Hsieh PP, Ho WL. Precocious puberty associated with growth hormone deficiency in a patient with craniopharyngioma: report of one case. Acta Paediatr Taiwan 2001; 42: 243–247.
19. De Vries L, Weintrob N, Phillip M. Craniopharyngioma presenting as precocious puberty and accelerated growth. Clin Pediatr 2003; 42: 181–184. doi: 10.1177/000992280304200213.
20. Moszczyńska E, Szalecki M, Pasternak-Pietrzak K, Jurkiewicz E, Szymańska S. Czaszkogardlak – epidemiologia, patogeneza, diagnostyka klinicznych i obrazowa. Endokrynol Ped 2017; 16: 205–220. doi: 10.18544/EP-01.16.03.1676.
21. Memon F, Humayun KN, Riaz Q, et al. Pediatric craniopharyngioma: a 20-year study on epidemiological features, clinical presentation, and survival outcomes in a tertiary care center from LMIC. Childs Nerv Syst 2024; 40: 427–434. doi: 10.1007/s00381-023-06177-8.
22. Mushtaq A, Fayaz M, Bhat AR, et al. Comprehensive Analysis of Craniopharyngioma: Epidemiology, Clinical Characteristics, Management Strategies, and Role of Radiotherapy. Cancer Diagn Progn 2024; 4: 521–528. doi: 10.21873/cdp.10358.
23. Craus S, Gruppetta M. Epidemiology of craniopharyngiomas: a population-based study in Malta. Endocr Oncol 2021; 1: 9–16. doi: 10.1530/EO-21-0006.
24. Palmisciano P, Young K, Ogasawara M, et al. Craniopharyngiomas Invading the Ventricular System: A Systematic Review. Anticancer Res 2022; 42: 4189–4197. doi: 10.21873/anticanres.15919.
25. Aghayan Golkashani H, Hatami H, Farzan A, et al. Tumors of the Central Nervous System: An 18-Year Retrospective Review in a Tertiary Pediatric Referral Center. Iran J Child Neurol 2015; 9: 24–33.
26. Greuter L, Guzman R, Soleman J. Typical Pediatric Brain Tumors Occurring in Adults-Differences in Management and Outcome. Biomedicines 2021; 9: 356. doi: 10.3390/biomedicines9040356. 
27. Alboqami MN, Khalid S Albaiahy A, Bukhari BH, et al. Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective. Heliyon 2024; 10: e32112. doi: 10.1016/j.heliyon.2024.e32112.
28. Otte A, Müller HL. Childhood-onset Craniopharyngioma. J Clin Endocrinol Metab 2021; 106: e3820–e3836. doi: 10.1210/clinem/dgab397.
29. Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62: 397–409. doi: 10.1111/j.1365-2265.2005.02231.x.
30. Larkin SJ, Ansorge O. Pathology and pathogenesis of craniopharyngiomas. Pituitary 2013; 16: 9–17. doi: 10.1007/s11102-012-0418-4.
31. Zhou Z, Zhang S, Hu F. Endocrine Disorder in Patients With Craniopharyngioma. Front Neurol 2021; 12: 737–743. doi: 10.3389/fneur.2021.737743.
32. Hoffmann A, Boekhoff S, Gebhardt U, et al. History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long-term prognosis. Eur J Endocrinol 2015; 173: 853–862. doi: 10.1530/EJE-15-0709.
33. Mallucci C, Gan Wei-Hoong, Morillon P, et al. Craniopharyngioma. Guideline for the management of children and young people [CYP] with craniopharyngioma up to the age of 19 years. Children’s Cancer and Leukaemia Group, London 2021; 7–29.
34. Nielsen EH, Jørgensen JO, Bjerre P, et al. Acute presentation of craniopharyngioma in children and adults in a Danish national cohort. Pituitary 2013; 16: 528–535. doi: 10.1007/s11102-012-0451-3.
35. Gan Wei-Hoong. Management of paediatric craniopharyngioma. ESPE Newsletter 2024; 65: 6.
36. Friedrich C, Beckhaus J, Muller HL. Radiation therapy in craniopharyngioma. ESPE Newsletter 2024; 65: 5.
37. Bogusz A, Boekhoff S, Warmuth-Metz M, Calaminus G, Eveslage M, Müller HL. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect 2019; 8: 481–492. doi: 10.1530/EC-19-0074. 
38. Daubenbüchel AM, Müller HL. Neuroendocrine disorders in pediatric craniopharyngioma patients. J Clin Med 2015; 4: 389–413. doi: 10.3390/jcm4030389. 
39. Hofmann BM, Hoelsken A, Fahlbusch R, Blümcke I, Buslei R. Hormone receptor expression in craniopharyngiomas: a clinicopathological correlation. Neurosurgery 2010; 67: 617–625. doi: 10.1227/01.NEU.0000372918.68453.5B.
40. Shen L, Sun CM, Li XT, Liu CJ, Zhou YX. Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis. Neurol Sci 2015; 36: 1859–1867. doi: 10.1007/s10072-015-2269-z.
41. Alotaibi NM, Noormohamed N, Cote DJ, et al. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis. World Neurosurg 2018; 109: 487–496.e1. doi: 10.1016/j.wneu.2017.09.164.
42. Losa M, Castellino L, Pagnano A, Rossini A, Mortini P, Lanzi R. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. J Clin Endocrinol Metab 2020; 105: dgaa089. doi: 10.1210/clinem/dgaa089.
43. Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103: 2761–2784. doi: 10.1210/jc.2018-01175. 
44. Grimberg A, DiVall SA, Polychronakos C, et al. Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr 2016; 86: 361–397. doi: 10.1159/000452150.
45. Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, et al. Safety of growth hormone [GH] treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary 2021; 24: 810–827. doi: 10.1007/s11102-021-01173-0. 
46. Follin C, Erfurth EM. Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors. Curr Treat Options Oncol 2016; 17: 50. doi: 10.1007/s11864-016-0426-0.
47. Xu Y, Sun Y, Zhou K, et al. Cranial irradiation alters neuroinflammation and neural proliferation in the pituitary gland and induces late-onset hormone deficiency. J Cell Mol Med 2020; 24: 14571–14582. doi: 10.1111/jcmm.16086.
48. Vatner RE, Niemierko A, Misra M, et al. Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. J Clin Oncol 2018; 36: 2854–2862. doi: 10.1200/JCO.2018.78.1492.
49. Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol 2015; 33: 492–500. doi: 10.1200/JCO.2014.56.7933.
50. Rose SR, Carlsson M, Grimberg A, et al. Response to GH Treatment After Radiation Therapy Depends on Location of Irradiation. J Clin Endocrinol Metab 2020; 105: e3730–e3741. doi: 10.1210/clinem/dgaa478.
51. Palczewska I, Niedzwiedzka Z. Wskaźniki rozwoju somatycznego dzieci i młodzieży warszawskiej [Somatic development indices in children and youth of Warsaw]. Med Wieku Rozwoj 2001; 5 (2 Suppl 1): 18–118.


Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty Mednauka
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć Biblioteka podcastów
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2026 Termedia Sp. z o.o.
Developed by Termedia.